Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies

Zydus Lifesciences has entered into exclusive negotiations to purchase from PAI Partners and Amplitude Surgical’s management, as well as two minority shareholders, 85.6 per cent of the share capital of Amplitude Surgical, for €6.25 per Amplitude Surgical share. The acquisition price represents an 80.6 per cent premium over the last closing price as of 10/03/2025 and a premia of 88.2 per cent and 92.2 per cent over the three-month and six-month volume-weighted average price of Amplitude Surgical respectively.

Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies. In the fiscal year ended June 30, 2024, Amplitude Surgical generated sales of €106.0mn and EBITDA of €27.1mn on a consolidated basis under IFRS. For the six months ended December 31, 2024, Amplitude Surgical’s consolidated sales amounted to €51.5 million (a growth of 5 per cent Y-o-Y at current exchange rates) with an EBITDA margin of approximately 25.4 per cent (unaudited figures).

Dr Sharvil Patel, MD, Zydus Lifesciences, said, “In Amplitude Surgical, we see several medium-term and long-term growth opportunities with respect to portfolio, capabilities, manufacturing and geographies.”

Olivier Jallabert, CEO and Founder, Amplitude Surgical, said, “The Amplitude Surgical team and I are delighted to join Zydus. This acquisition by a worldwide healthcare leader is a testament to the successful development of the Company over the last 25+ years, originally as a national orthopaedics challenger and today as a European leader. I would like to thank PAI Partners for their trust and continuous support in our growth journey. We have demonstrated our resilience in periods of uncertainty while driving the transformation of the company, developing our commercial, industrial, and technological capabilities.”

Stefano Drago, Founding Partner, PAI Mid-Market Fund, PAI Partners, said, “We are delighted to have supported Amplitude Surgical's transformation into a European leader in lower-limb orthopaedics, with a particular focus on innovation. Over the last four years, the company has reinforced its market position, delivered a strong financial performance based on continuous product development, successfully disposed of a non-core business and streamlined operational processes while developing a new state-of-the-art manufacturing facility in France and an innovative surgical robot. Thank you to Olivier Jallabert and his fantastic team for their partnership.”